Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chenodeoxycholic acid - Leadiant Biosciences

Drug Profile

Chenodeoxycholic acid - Leadiant Biosciences

Alternative Names: Chenix; Chenodiol; Chenofalk; LB-101 - Leadiant Biosciences; LB101; Xenbilox

Latest Information Update: 21 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dr Falk Pharma
  • Developer Leadiant Biosciences; Solvay
  • Class Choleretics; Cholic acids; Gallstone therapies; Gastrokinetics; Irritable bowel syndrome therapies
  • Mechanism of Action Cholesterol modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn error metabolic disorders; Cerebrotendinous xanthomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholestasis
  • Registered Cerebrotendinous xanthomatosis

Most Recent Events

  • 15 Feb 2024 Leadiant Biosciences plans a phase III trial for Cerebrotendinous xanthomatosis (Newly-diagnosed, In children, In adolescents, In adults, In the elderly) (PO, Capsule) in March 2024 (NCT06260748) (EudraCT2023-505759-29-00)
  • 22 Mar 2022 Phase-III development in Cerebrotendinous xanthomatosis is ongoing in USA (Leadiant Biosciences pipeline, March 2022
  • 01 Jun 2019 Phase-III clinical trials in Cerebrotendinous xanthomatosis in USA (PO) (Leadiant Biosciences pipeline, June 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top